Holen Sie sich die Stockscreener-App
173.80
0.68%
1.18
Handel nachbörslich:
173.80
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$172.62
Offen:
$171.78
24-Stunden-Volumen:
996.24K
Relative Volume:
0.51
Marktkapitalisierung:
$25.50B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.63
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+3.10%
1M Leistung:
-0.52%
6M Leistung:
+35.94%
1J Leistung:
+21.75%
1-Tages-Spanne:
$171.65
$175.29
1-Wochen-Bereich:
$160.36
$175.29
52-Wochen-Spanne:
$110.03
$190.20
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
173.80 | 25.32B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,087.38 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.49 | 525.25B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.11 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.00 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.23 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX) and Biogen (BIIB) - The Globe and Mail
Postpartum Depression Drugs Market Size to Surpass USD 1.97 Billion by 2033, Due to Increasing Awareness & Fast Development of Pharmaceuticals – SNS Insider - GlobeNewswire Inc.
Priya Singhal’s Blueprint For Biogen’s Next Act - Citeline News & Insights
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Gene Therapy Market Innovations and Key Players: Biogen, - openPR.com
Rakuten Investment Management Inc. Buys Shares of 198,572 Biogen Inc. $BIIB - MarketBeat
Patient Capital Management LLC Has $55.56 Million Stake in Biogen Inc. $BIIB - MarketBeat
Biogen’s High Dose Spinraza Win Extends SMA Treatment Options In EU - simplywall.st
Massachusetts Financial Services Co. MA Purchases 11,685 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - Yahoo Finance
40 Under 40: Kevin Conway, Biogen - Medical Marketing and Media
(BIIB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease - ADVFN
Zacks Research Has Positive Estimate for Biogen Q4 Earnings - MarketBeat
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money? - AD HOC NEWS
SG Americas Securities LLC Trims Holdings in Biogen Inc. $BIIB - MarketBeat
Strong Cash Yield: Is Biogen Stock A Buy? - Trefis
Biogen Inc.: Can an Aging Neurology Giant Reinvent Itself Around Alzheimer’s? - AD HOC NEWS
Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st
June 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen Inc. (NASDAQ:BIIB) Short Interest Update - MarketBeat
Nordea Investment Management AB Has $18.20 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Wednesday when compared to competitors - MSN
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Genentech, NoNO, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell - Barchart.com
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha
Europe clears Biogen’s high-dose Spinraza regimen - The Pharma Letter
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - Sahm
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate the Biotech Pack? - AD HOC NEWS
Biogen (NASDAQ:BIIB) Shares Down 5.9%Time to Sell? - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Biogen falls after flagging $222 million charge to profit in Q4 - TradingView — Track All Markets
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence - BioSpace
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com Australia
What to Expect From Biogen's Next Quarterly Earnings Report - Yahoo Finance
Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4 - Nasdaq
Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus
Biogen (BIIB) Anticipates Q4 Earnings Impact Due to R&D Costs - GuruFocus
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly By Investing.com - Investing.com South Africa
Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share - MSN
Biogen Expects Q4 Expense of $222 Million - marketscreener.com
Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail
BiogenCharge to impact Q4 net income by $1.26 per shareSEC filing - marketscreener.com
Biogen’s Q4 preliminary EPS comes in below consensus By Investing.com - Investing.com Canada
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg
The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.69%
1.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):